Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nader Noorian

Internal Medicine Mission Viejo, CA Medical Doctor

NPI 1861479057 CMS profile 175479

26800 Crown Valley Pkwy, Suite 305, Mission Viejo, CA 92691

Open in the dashboard

General payments

$37,517

1,486 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nader Noorian of Mission Viejo, CA is reported in the CMS Open Payments database as having received $37,517 across 1,486 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,122 236
2024 General $7,479 187
2023 General $3,708 203
2022 General $4,661 250
2021 General $4,643 219
2020 General $2,402 116
2019 General $6,502 275

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nader Noorian
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nader Noorian were reported at $8,122. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nader Noorian Internal Medicine median Middle half National median
2019 $6,502 $159 $48–$570 $163
2020 $2,402 $119 $33–$402 $114
2021 $4,643 $135 $37–$521 $132
2022 $4,661 $141 $42–$496 $149
2023 $3,708 $149 $45–$519 $160
2024 $7,479 $154 $47–$537 $164
2025 $8,122 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $7,857 63 payments
  2. Lilly USA, LLC $3,296 168 payments
  3. AbbVie, Inc. $3,015 139 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $2,680 95 payments
  5. Amgen Inc. $1,756 74 payments
  6. Novo Nordisk Inc $1,716 101 payments
  7. Novartis Pharmaceuticals Corporation $1,584 102 payments
  8. Janssen Pharmaceuticals, Inc $1,584 56 payments
  9. Pfizer Inc. $1,397 99 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $1,380 78 payments
  11. Other $11,250 511 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $32,328 1,470 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,050 7 payments
  3. Education $110 7 payments
  4. Consulting Fee $25 1 payment
  5. Travel and Lodging $5 1 payment
Products named General payments · program years 2019–2025
  1. AIRSUPRA $5,971 23 payments
  2. FARXIGA $1,694 33 payments
  3. XARELTO $1,533 55 payments
  4. Kerendia $1,380 78 payments
  5. TRULICITY $1,269 71 payments
  6. JARDIANCE Diabetes $1,234 35 payments
  7. LEQVIO $1,191 78 payments
  8. MOUNJARO $1,148 54 payments
  9. Repatha $1,064 48 payments
  10. JARDIANCE Diabetes $1,001 37 payments
  11. Other $26,985 1,448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 185 drugs

Part D claims

15,609

Median for Internal Medicine: 777

Drug cost

$1,847,175

Median for Internal Medicine: $73,373

Branded share of claims

20.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 275 $339,844
Ozempic Semaglutide Brand 216 $221,271
Eliquis Apixaban Brand 158 $169,654
Trulicity Dulaglutide Brand 104 $127,333
Jardiance Empagliflozin Brand 99 $120,790
Januvia Sitagliptin Phosphate Brand 74 $82,725
Myrbetriq Mirabegron Brand 95 $82,374
Farxiga Dapagliflozin Propanediol Brand 72 $67,606
Kerendia Finerenone Brand 52 $58,362
Xarelto Rivaroxaban Brand 45 $55,038

The 10 drugs with the highest cost, of 185 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$247,193

Of which drugs: $15,149

Medicare patients

669

Average age 77

Services billed

13,774

293 women, 376 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 42%
Diabetes 36%
Chronic kidney disease 25%
Atrial fibrillation 22%
Depression 20%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 30 30 $8,716
Vaccine for influenza for injection into muscle 90653 Office 69 69 $5,646

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$3,894 — —
JARDIANCE
$551 99 —
MOUNJARO
$301 275 —
Kerendia
$295 52 —
XARELTO
$291 45 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

1,486 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record